Cite
Shoumariyeh K, Jung J, Rassner M, et al. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. Ann Hematol. 2021;100(6):1637-1640doi: 10.1007/s00277-021-04490-3.
Shoumariyeh, K., Jung, J., Rassner, M., Dold, S. M., Riebl, V., Pantic, M., Herget, G., Marks, R., Lübbert, M., Wäsch, R., & Engelhardt, M. (2021). Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. Annals of hematology, 100(6), 1637-1640. https://doi.org/10.1007/s00277-021-04490-3
Shoumariyeh, Khalid, et al. "Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab." Annals of hematology vol. 100,6 (2021): 1637-1640. doi: https://doi.org/10.1007/s00277-021-04490-3
Shoumariyeh K, Jung J, Rassner M, Dold SM, Riebl V, Pantic M, Herget G, Marks R, Lübbert M, Wäsch R, Engelhardt M. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. Ann Hematol. 2021 Jun;100(6):1637-1640. doi: 10.1007/s00277-021-04490-3. Epub 2021 Mar 13. PMID: 33712868; PMCID: PMC8116235.
Copy
Download .nbib